Mechanisms of RET signaling in cancer: current and future implications for targeted therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• RET signaling pathway dysregulation, through mutation, rearrangement, or overexpression, is a key driver in neuroendocrine and epithelial cancers like thyroid, breast, and lung.
• Understanding the specific mechanisms of RET signaling deregulation and its role in tumor progression is critical for developing effective cancer treatments.

Purpose of the Study:

• To review the distinct mechanisms of RET signaling in various human cancers.
• To summarize current knowledge on small molecule inhibitors targeting the RET tyrosine kinase domain for therapeutic applications in RET-positive cancers.

Main Methods:

• Literature review of scientific articles and clinical studies.
• Analysis of RET signaling pathways and their oncogenic roles.
• Summary of small molecule inhibitor development and efficacy in preclinical and clinical settings.

Main Results:

• Identified diverse mechanisms of RET signaling deregulation across different cancer types.
• Highlighted the therapeutic potential of targeting the RET tyrosine kinase domain with small molecule inhibitors.
• Provided an overview of current and emerging targeted therapies for RET-driven cancers.

Conclusions:

• Targeting RET signaling pathways offers a promising therapeutic strategy for RET-positive cancers.
• Further research into RET signaling mechanisms and inhibitor development is crucial for advancing cancer treatment.
• Personalized medicine approaches focusing on RET alterations can improve patient outcomes.